Equilibrated Atomic Models of Outward-Facing P-glycoprotein and Effect of ATP Binding on Structural Dynamics

Lurong Pan & Stephen G. Aller

Department of Pharmacology and Toxicology, University of Alabama at Birmingham, 1025 18th Street South, Birmingham, AL, 35205 USA.

P-glycoprotein (Pgp) is an ATP-binding cassette (ABC) transporter that alternates between inward- and outward-facing conformations to capture and force substrates out of cells like a peristaltic pump. The high degree of similarity in outward-facing structures across evolution of ABC transporters allowed construction of a high-confidence outward-facing Pgp atomic model based on crystal structures of outward-facing Sav1866 and inward-facing Pgp. The model adhered to previous experimentally determined secondary- and tertiary- configurations during all-atom molecular dynamics simulations in the presence or absence of MgATP. Three long lasting (>100 ns) meta-stable states were apparent in the presence of MgATP revealing new insights into alternating access. The two ATP-binding pockets are highly asymmetric resulting in differential control of overall structural dynamics and allosteric regulation of the drug-binding pocket. Equilibrated Pgp has a considerably different electrostatic profile compared to Sav1866 that implicates significant kinetic and thermodynamic differences in transport mechanisms.

P-glycoprotein (Pgp/ABCB1) is an ATP-binding cassette (ABC) transporter and perhaps the most promising drug pump known in nature. The function of Pgp has been likened to a hydrophobic "vacuum cleaner" in which it intercepts small molecules within the inner leaflet of the lipid bilayer and forces them to the outer leaflet or even directly out of cells. Pgp provides a critical function in protecting cells from herbicides and other xenotoxins, but in the case of chemotherapies, Pgp can be a major cause of multidrug resistance. Pgp recognizes an extraordinarily large number of diverse molecules. To date, thousands of chemically different and therapeutically important substrates have been identified with molecular weights ranging from 360 dalton (aldosterone), ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide. The original x-ray structure of mouse Pgp revealed inward-facing conformations with drugs bound, ~1.2 kD (valinomycin and cyclosporin A) and even the 4 kD amyloid peptide.
Results and Discussion

Secondary and tertiary structure validity. Protein secondary structure generally remains unchanged during conformational cycling of enzymes under physiological condition to avoid unfolding or misfolding during catalytic cycling. ABC transporters are expected to have a highly stable secondary structure throughout conformational dynamics due to biophysical constraints of the bilayer and from what is already known about tertiary structure. Approximately 30% of Pgp is embedded in the membrane where the low dielectric field will tend to maintain alpha helices. Another ~40% of Pgp is represented as nucleotide binding domains (NBDs), which are the most conserved domains in the ABC superfamily. Multiple crystal structures of ABC transporters show that the NBD secondary- and tertiary- structures do not significantly vary between inward- and outward- facing conformations. Furthermore, Pgp secondary structure does not change during its catalytic cycle based on experimental observations. Unbiased all-atom MD simulations of the mouse Pgp homology model based on full equilibration and sufficient sampling size (Text S1 and Figure S1) showed completely stable secondary structure components across the entirety of six independent simulations including consistent folded helix and beta sheet components (Figure S2). The average secondary structure components based on the last 50 ns of trajectories (Figure S3) reveal that the total secondary structure components of Pgp are also conserved between orthologs and between any given conformation regardless of outward-facing (Sav1866 and homology model), inward-facing (mouse Pgp crystal structures) or intermediates (MD simulation end points). In our simulations, ~95% of the secondary structure remained essentially unchanged throughout conformational dynamics. The slight fluctuation was due to dynamic features of the protein in the connecting regions between two distinct secondary structure components due to fluctuating \( \varphi \) and \( \psi \) angles. These local regions of Pgp fluctuated between two or three dominant secondary structures in a highly dynamic manner (Figure S4).

Inter-TM packing and helix registry of outward-facing Pgp initial model and equilibrated models was validated by previous disulfide crosslinking experiments based on double cysteine mutation (5–7 Å Cu-phenanthroline spacer). The following pairs were previously observed to form disulfide bonds and are mapped to atomic structures in Figure 1: L328-L971 (L332-L975 in human Pgp) between TM6 and TM12; V129-G935 (V133-G939 in human Pgp) and C133-A931 (C137-R935 in human Pgp) between TM2 and TM12; N292-G770 (N296-G774 in human Pgp) and G296-F766 (G300-F770 in human Pgp) between TM5 and TM8; pairs between TM3 and TM9 as D173-N816 (D177-N820 in human Pgp) and L171-N816 (L175 and N820 in human Pgp). Most residue pairs maintain direct contact between inward-facing and outward-facing conformations except for the three conformation-sensitive pairs L328-L971, D173-N816 and L171-N816. The C\( \alpha \) distance of residue pair L328-L971 is 12.4 Å apart in the inward-facing crystal structure (PDB: 4M1M, Figure 1A) but is 19.8 Å in the outward-facing conformation due to the opening of the drug pocket to the outer leaflet (Figure 1B). The formation of a disulfide bond would lock the protein in the inward-facing conformation, which explains the inhibition of verapamil-stimulated ATPase activity. The C\( \alpha \) distances of residue pair L328-L971 in the outward-facing structures are in strong agreement with existing crosslinking data. We conclude from crosslinking experiments and the equilibrated structure of Pgp-MgATP showed little change in the pairwise distances except for L328-L971 due to partial closing of ECL1-ECL3.

Other crosslinks, including various pairs between TM1-TM11, maintain similar positions between the inward-facing and outward-facing conformation and slightly favor the outward-facing conformation. Several cross-linked pairs at TM4/TM5-TM12 and at TM6-TM10/TM11 are also compatible with the inward-facing crystal structures but are prevented in the outward-facing conformation, explaining inhibition of verapamil-stimulated ATPase activity when crosslinked. In addition, various pairwise positions in the drug-binding cavity between TM6, TM11 and TM12 are also compatible with both inward-facing and outward-facing structure. These structural features reveal the registry and rotation of the helices in the outward-facing structures are in strong agreement with existing crosslinking data. We conclude from crosslinking experiments and the structural comparison between inward-facing and outward-facing conformations that conformational changes during drug transport are governed primarily by shifts in inter-domain distances between TM6-TM12 and TM3-TM9 whereas other TMs maintain relatively fixed inter-domain packing.
Asymmetric features of mouse Pgp structure and dynamics. In contrast to the symmetric Sav1866 template, mouse Pgp has evolved with a high degree of asymmetry between its two "halves", which share only 59.4% sequence similarity. More specifically, 77.3% similarity lies between two NBDs and only 43.5% similarity between two halves of TMDs (Figure 2). The differences in the primary sequence result in the asymmetry of chemical properties between pseudo symmetric residues and patches. In general, charged residues (K, R, E, D) are highly hydrophilic with the largest entropy profiles whereas hydrophobic residues prefer to pack together and stabilize each other in the aqueous phase. Therefore, the analysis of different chemical properties based on the residue types of each region can help explain their different dynamics (Figure 2). Specifically, TM1 and TM2 (Figure 2 A) are 5-residues longer and with more charged residues than their pseudo symmetric domains TM6 and TM7 (Figure 2 A’). The intracellular end of TM3 (Figure 2B) has more charged residues than TM9 (Figure 2 B’). These features render larger mobility of half1 than half2 at TMDs. Even though the ATP-binding residues are conserved between site 1 and site 2 (Figure 3), their surrounding residues are substantially different. WA1 and WB1 are surrounded by more charged residues (Figure 2 D and E) than WA2 and WB2 (Figure 2 D’ and E’). Whereas LSGGQ2 is surrounded by more charged residues (Figure 2 C and F’) than that of LSGGQ1 (Figure 2 C’ and F’). In sum, our observations reveal a more hydrophilic site 1 (WA1 + WB1 + LSGGQ2) than site 2 (WA2 + WB2 + LSGGQ1) and indicate different thermodynamics and kinetics between the two sites, consistent with multiple findings in the literature. A previous MD study was performed using the inward-facing conformation with ATP bound at each of the Walker A motifs but with both LSGGQ motifs completely dissociated. Even though the study was done at the near-opposite conformation and different ATP binding environment compared to our study, asymmetric structural dynamics between two NBDs was also observed. The asymmetry between the two halves of Pgp must therefore play a major role in the overall function and mechanism of the transporter.

The root-means-square fluctuation (RMSF) (Figure 4) reveals asymmetric dynamics of apo-Pgp in equilibrated states (Figure 4, blue line). The results suggested that MgATP-binding reduced flexibility and introduced more symmetry to the protein dynamics (Figure 4, red line). In general, apo-Pgp has larger RMSF than Pgp-MgATP across all regions. Certain locations are particularly noteworthy: ECL1 (Figure 4, peak A) has the largest RMSF of the entire structure for both apo-Pgp (3.5 Å) and Pgp-MgATP (2.8 Å). ECL4 (Figure 4, peak A’) has the biggest RMSF of the TMs in half2. In apo-Pgp, ATP-binding site 1 (Figure 4 peak B, peak C, peak D, peak E and peak F) is more flexible than site 2 (Figure 4 peak B’, peak C’, peak D’, peak E and peak F’). Specifically, MgATP-binding reduces the flexibility of all the ATP-binding signature motifs at NBDs: Walker A (WA1: G423NSGCGK429; WA2: G1067SSGCGK1072), Walker B (WB1: I547LLLDE552; WB2: I1192LLLDE1197), LSGGQ (LSGGQ 1: L 527SGGQ531; LSGGQ2: L 1172SGGQ1176), A-loop (A-loop1: Y397P400S403; A-loop2: Y1040P1043). In addition, ATP-binding also reduced the flexibility of TMDs at various levels, which reveals an allosteric effect of nucleotide binding to the TMDs.
Three distinctive meta-stable states of ATP-binding. While MD is a powerful technique for probing all-atom contributions to protein function, only nanosecond to microsecond timeframes are currently feasible for a system as large as Pgp (209,000 atoms). On the order of millisecond to second timescales would be required to observe a full catalytic cycle for an active transporter. In addition, MD is largely classical in mechanics as opposed to quantum, and therefore hydrolysis of chemical bonds, such as those in ATP, and the resulting release of energy, is not currently feasible to simulate by MD. However, MD simulations can access information in a small window of the catalytic cycle and provide value biochemical insights. In this work, we started with a scenario in which dual ATP-bound outward-facing Pgp was simulated by MD, and we observed the sequential events when ATP was removed from the system. ATP-binding represents one of the most conserved properties of all ABC transporters. An ATP-interaction map, based on the MD simulations is shown in Figure 3. All the binding residues are conserved between site 1 and site 2. The ATP-Mg$^{2+}$ binds to mouse Pgp as in Figure S5. The H-bonds and coordination bonds started in the range between 1.63–2.20 Å in the initial structure (2.5 Å cutoff was used as the definition). All bonding interactions between ATP-Mg$^{2+}$ and Walker A/Walker B stayed within the cutoff with remarkable stability but the interactions between ATP and LSGGQ motifs resulted in distinct meta-states.

A previous study used steered MD (SMD) to probe the effect of conformational change on drug-binding. In this case, the two ATP binding sites were equilibrated separately and the ATP site in NBD1 included an engaged E556 residue (mouse-Pgp E552) whereas ATP binding at NBD2 had a disengaged E1201 residue (mouse Pgp E1197). A skewed NBD orientation was observed in both cases in their study. We note that SMD requires placing restraints on the protein and the application of bias forces in order to cause a relatively fast conformational change within a short timeframe. We describe the first unrestrained (unbiased) MD study of outward-facing Pgp in which both Mg-ATP were placed at canonical binding sites and equilibrated simultaneously. We found that both E552-Mg$^{2+}$ and E1197-Mg$^{2+}$ were engaged with nucleotide throughout the entire duration of all simulations. The interactions are very strong, since both glutamates were associated with Mg$^{2+}$ as bidentate clamps. Taken together, double-occlusion of two ATPs help stabilize an NBD sandwich configuration (proper NBD alignment) prior to a hydrolysis event.

In order to better demonstrate the conformational effects in NBDs upon MgATP binding, C$_{\alpha}$ distance between the pairs K429-S1173 (site 1) and K1072-S528 (site 2) were monitored over time (Figure 5). In apo-Pgp, both ATP-binding site 1 and site 2 (Figure 5A and C) demonstrated constant fluctuations between these residue pairs. However, site 1 showed a larger flexibility than that of site 2. The residue distance at site 1 also increased up to 20 Å whereas the residue distance at site 2 remained below 12 Å. A larger separation of NBDs at site 1 compared to site 2 was a consistently observed feature. On the other hand, MgATP-binding markedly stabilized the residue

![Figure 2 | Comparison of the pseudo-symmetric halves of mouse-Pgp.](image)

![Figure 3 | Pgp-MgATP Contact Map.](image)
Pgp requires the presence of phospholipids, which are present in the absence of Pgp substrates. However, any ATPase activity of hydrolysis in the absence of drug.

Conserving or "halting" mechanism which could prevent ATP hydrolyzable "double-loose occluded" state may implicate an ATP bond is not formed in "double-loose occluded" state. The non-

Previous work has characterized alternating access mechanisms of ATP-binding and hydrolysis of Pgp. Our MD simulations support these observations but also provide atomistic details of several different proposed meta-stable occluded nucleotide-bound states of Pgp. The simulations of Pgp-MgATP may represent catalytic states previously characterized in which, in the absence of substrate, the complex adopts either a high affinity "double-tight occluded" resting state (Figure 5 E-E2) or a low affinity "double-loose occluded" resting state (Figure 5 F-F2) with both nucleotides bound. These kinetic studies also showed that drug-binding facilitates the ATP-binding pocket shift from either resting state to a "lose-tight occluded" transition state in which only one ATP is tightly bound (Figure 5 G-G2). In "double-loose occluded", both LSGGQ motifs in each binding site shift the binding from the O$_2$ of ATP to the O$_a$ that are shared by both ATP and ADP. A previous biochemical experiment shows that the mutation of S528A and S1173A together completely disabled the ATPase activity of mouse-Pgp. The binding of ATP(Ogamma)-S528/S1173(HG) is required for ATP hydrolysis but this bond is not formed in "double-loose occluded" state. The non-hydrolyzable "double-loose occluded" state may implicate an ATP conserving or "halting" mechanism which could prevent ATP hydrolysis in the absence of drug.

The so-called "basal" ATPase activity of Pgp is routinely observed in the absence of Pgp substrates. However, any ATPase activity of Pgp requires the presence of phospholipids, which are present in the detergent 'mixed' micelles surrounding purified Pgp preparations or when Pgp is reconstituted into liposomes. The lipids, in principle, would thus have to access the hydrophobic cavity of Pgp as with other substrates. Indeed, a previous study has shown that lipids, especially short chain phosphatidyl cholines, are transported by Pgp. It is highly likely therefore, that "basal" ATPase activity is a normal consequence of occasional lipid flipase activity of Pgp occurring in detergent micelles, liposomes or the cell membrane. In this case, lipid and drug substrate could cause similar structural dynamic effects on Pgp if they gain full access to the substrate-binding pocket. We therefore propose that partial intrusion of lipids as seen in our simulations prompt less favorable NBD alignment compared to proper binding of a substrates. This model could be therefore described as a "primed" state, which allows Pgp longer time to sample higher-affinity inward-facing conformations for completely enveloping substrates prior to collapse and transport.

The "loose-tight occluded" conformation (Figure 5 G-G2) is in agreement with an asymmetric state identified in a kinetic study in which one low affinity (K_d = 0.74 mM) site and one "occluded" high affinity (K_d = 6 μM) site appeared after the ejection of the drug. After drug ejection, the hydrolyzed site 1 is proposed to avoid adopting a conformation that will result in another ATP hydrolysis event before the protein resets to an inward-facing conformation. Inward-facing conformations are also more accessible to ATP exchange to prepare for another round of the drug transport cycle. The "loose-tight occluded" conformation is also in agreement with the previous kinetic studies in which site 2 demonstrated increased stability and decreased accessibility after site 1 is hydrolyzed during drug ejection. The equilibrated conformation of apo-Pgp from our simulation also suggested that hydrolysis of site 2 is crucial to the transformation of Pgp from the outward-facing conformation to the inward-facing conformation. We extended one apo-Pgp simulation to 400 ns, but no opening was observed at site 2, which suggested that extra thermal energy beyond background levels and static expulsion between ADP and Pi generated from ATP hydrolysis is likely required for site 2 to disengage and allow dissociation of NBDs.

**Figure 4** Root-mean-square fluctuation (RMSF) per residue at equilibrium. The RMSFs are measured using the Cα of each residue from trajectories of the last 50 ns simulations and are averaged over triplicate simulations for both apo-Pgp and Pgp-MgATP in red. 2D cartoon representatives of the secondary structures are in pink. Domains are shown in the same sequence order as that of the RMSF (helix as spring, coil and turn as straight line, beta sheet as arrow). The Figures of the two pseudo-symmetric halves (half1: residue 40-626, half2: residue 688-1271) are displayed in parallel for comparison. Labeled regions are region A (ECL1), region A’ (ECL4), region B (IH1), region B’ (IH3), region C (A-loop1), region C’ (A-loop2), region D (WA1), region D’ (WA2), region E (LSGGQ1), region E' (LSGGQ2), region F (WB1), region F’ (WB2). In apo-Pgp, ATP-binding site 1(B + C + D + E’ + F) is more flexible than site 2 (B’ + C’ + D’ + E + F’).
Conformational change and allosteric regulation of ATP-binding

The conformational changes were monitored using residue pairs from pseudo-symmetric counterparts (Figure 6). Six different averaged pair distances at the “extracellular gate” in the six simulations demonstrated large randomness in this region (Figure 6A). Therefore, large flexibility and numerous meta-stable states with similar energy are implicated. In addition, it was also shown that the three residue pairs are strongly inter-correlated in distance patterns, which suggests that the opening/closing of the extracellular gate occurs simultaneously for all TMs. When compared to the initial structure, the A79-T736 pair distance markedly decreased for all simulations whereas the other pairs at the extracellular gate fluctuated within a small dynamic range from the initial distance (Figure 6A, G and H). The simulations demonstrate that the dynamic structure of the extracellular gate oscillates between open and closed forms rather than a relatively fixed conformation.

In our simulations, the apo-Pgp adopts an “A” shape at the drug-binding pocket open towards intracellular direction (Figure 6I) whereas Pgp-MgATP adopts a “V” shape open towards extracellular direction (Figure 6J). The result indicates that MgATP-binding potentiates the outward-facing conformation by promoting the opening of TM1-TM7 at the higher end of drug-binding pocket and the closing of TM6-TM12 at the low drug-binding pocket.

Figure 5 | Effect of ATP on conformation dynamics and stability. The MgATP, K429/K1072 (2xWalker A), and S1173/S528 (2xLSGGQ) are drawn in licorice with H in white, N in blue, C in cyan, O in red, P in gold and Mg<sup>2+</sup> in pink. The C<sub>a</sub> of the ATP binding residues are drawn as green spheres, pairwise distances are drawn in dashed lines (E-G). H-bonds <2.5 Å are in solid black lines and H-bonds >2.5 Å are in dashed lines (E1, E2, F1, F2, G1 and G2). Orange arrows point to the directions of conformational change (F1, F2 and G1). The protein is shown in cartoon with half1 in pink and half2 in ice blue. (A) site 1 residue pair K429(WA)-S1173(LSGGQ) and (C) site 2 residue pair K1072(WA)-S528(LSGGQ) from the three apo-Pgp simulations. The same residue pairs in the three simulations of Pgp-MgATP are shown in (B) (site 1) and (D) (site 2). Conformation 1, “double-tight occluded” (E) (equilibrated structure from run3) consists of ATP in a tight sandwich at site 1 (E1) and site 2 (E2) with the K-S distance of ~9.4 Å. Conformation 2, “double-loose occluded” (F) (equilibrated structure from run2) is at loose sandwich between Walker A and LSGGQ with the K-S distance of ~11.1 Å due to the shift of ATP(O<sub>c</sub>)-S528/S1173(HG) to ATP(O<sub>a</sub>)-S528/S1173(HG) at both site (F1, F2). This conformation has a slightly tilted Walker A to the intracellular direction and tilted LSGGQ to the membrane direction for both sites. Conformation 3, “loose-tight occluded” (G) (equilibrated structure from run1) adopts detached LSGGQ on site 1 (G1) with a K-S distance of 12.2 Å and the ATP locked site 2 (G2) with a K-S distance of ~9.4 Å.
**Figure 6** Conformational change illustrated with landmark residues. Landmark residue distances at each regions of the protein are measured using the average of the last 50 ns trajectories from each simulation. The protein is shown as cartoon representation with half1 in pink and half2 in ice blue. The Cα of the landmark residues are drawn as spheres in green (D-L). P atoms of lipid bi-layer are drawn in semi-transparent sphere in gold. MgATP is drawn in licorice with H in white, N in blue, C in cyan, O in red, P in gold and Mg²⁺ in pink. Orange arrows point to the directions of conformational change. The conformational changes are monitored using residue pair from two pseudo-symmetric counterparts: Extracellular gate (A) uses A79-T736 (ECL1-ECL3), G207-G850(TM3-TM9), G325-E968(ECL2-ECL4), drug binding pocket (B) uses higher end F71(TM1)-F728(TM7) pair and lower end Q343 (TM6)-Q986 (TM12) pair, ATP-binding sites (C) uses K429-S1173 (site 1) and K1072-S528 (site 2). The predominant conformation observed from all three runs of apo-Pgp (E, G, I and K) and predominant conformation observed from 30 ns-100 ns of run1, 30-50 ns of run2 and 30-200 ns of run3 of Pgp-MgATP (F, H, J and L) are different in various aspects.
Even though these simulations did not include substrates, the ejection of drug would require a "V" shape of the drug-binding pocket and not a top blocked "A" shape as observed in the inward-facing conformation. In addition, a stronger correlation was observed in conformational change between site 1 (K429-S1173) and TMDs (Q343-Q986) than that of site 2 (K1072-S528) (Figure 6B and C). This suggests the possibility that the activity of site 1 is the dominant "thermal engine" while TM6 is the "transmission" for the conformational change of the drug-binding pocket.

In one study, the crosslinking of the upper region of TMDs was affected by ATP binding at the NBDs. Specifically, ATP binding inhibited the crosslink of pairs of human Pgp between TM6 and TM12 at L339C-V996C (mouse L334-V978) and L322C-L975C (mouse L328-L971) but promoted the crosslink of F343C-V982C (mouse F339-V978). In our equilibrated trajectory, the Cz distance between F339-V978 (10.41 Å) is ~5 Å shorter than that of L334-V978 (15.5 Å) and L328-L971 (16.4 Å) pairs and therefore F339-V978 is more favored of disulfide formation than L334-V978 and L328-L971. The effect of ATP is to introduce and maintain an outward-facing conformation with a "V" shape at drug binding pocket that inhibits or promotes these crosslinks. Even though our simulations cannot describe the inward-facing to outward-facing transition triggered by ATP binding, the differences of these three residue pairs are clearly maintained in the simulations in the presence of ATP and is in agreement with the experimental observation. The same group conducted crosslinking experiments between the WalkerA-LSGGQ motifs and observed increased ATP hydrolysis. Since ATP hydrolysis requires a precise conformation of the WalkerA-LSGGQ sandwich, the crosslinking between the WalkerA-LSGGQ was suggested to essentially reduce the degrees of freedom for the NBDs enhancing alignment and hydrolysis. Our simulations showed a twisted (improper) NBD alignment in the absence of ATP binding (Figure 6K), which could indicate that a crosslink between the two NBDs assists the correction of a misalignment, favoring enhanced ATP binding. We did not simulate crosslinking per se, but our structure showed direct side-chain contact between the crosslinked pair LSGGQ (P517C) and Walker A (H1050C) (mouse P513-H1046) showing agreement between our homology model and the biochemical data.

In addition to ligand effects (drug-binding and ATP-binding/hydrolysis), water is a major driving force of protein conformational change by hydrophobic effect and hydrostatic pressure on both sides of the membrane. Solvent accessible surface area (SASA) is an indirect measurement for conformational change. For both models, SASA of TMDs decreases while the SASA of NBDs increases, which indicates that the closure of TMDs is coupled with the opening of NBDs. The results suggest water efflux from the TMDs and water influx into the NBDs due to the change of conformation in these areas (Figure 7). Such water flux is directly quantifiable using the change of SASA in percentage compared to that of initial structure. The results indicated that the efflux of water from the TMDs and the influx of water into the NBDs are strongly correlated processes. It also showed that the MgATP binding provided the counterforce in this process to maintain a different hydration distribution favoring the outward facing conformation as opposed to that of apo-Pgp, which favors the inward-facing conformation.

Residue type and electrostatic potential analyses between Pgp and Sav1866. The Sav1866 crystal structure was used as the template for the initial structure of the outward-facing conformation of mouse Pgp. However, the homology modeling process was not complete until MD simulation produced thermodynamically favored conformations. This was due to the differences in the electrostatic and hydrophobic properties between Sav1866 and mouse Pgp. The partial closure of TM6 was observed during equilibration for all simulations for mouse-Pgp regardless of ATP-binding. Our starting structure based on Sav1866 is more likely to represent a high-energy short-lived transition state that is driven by ATP hydrolysis at the moment of drug ejection. Residue type analysis (Figure 8) and electrostatic potential (Figure S6) analysis on both mouse Pgp and Sav1866 explains why each protein favored inward-facing- and outward-facing conformations, respectively, for crystallography. The analysis of residue type differences (Figure 8) reveals that only polar and nonpolar residues are included in the drug-binding pocket (Figure SA and C) of mouse Pgp whereas 9 pairs (18 total) of extra charged residues exist in the same region of Sav1866 (Figure 8B and D). The counterparts of the 18 charged residues in mouse Pgp are 4 aromatic residues, 5 hydrophobic residues and 9 neutral polar residues. The hydrophobicity of mouse Pgp in the drug-binding pocket is substantially larger than that of Sav1866. In addition, the position of the charged residues in Sav1866 would tend toward repulsion thereby promoting the outward-facing conformation with an open substrate pocket towards extracellular space (Figure 8D). The comparison in electrostatic potential shows an overall neutral region in mouse Pgp but highly charged region in Sav1866 at TMDs. In contrast, the interfaces between two NBDs in mouse Pgp (Figure S6 B1 and B2) are more charged than that of Sav1866 (Figure S6 B), which indicates more hydrophilic NBDs in mouse Pgp than Sav1866. Since the hydrophobic effect has a stronger attraction (~10 kcal/mol) than electrostatic interaction (~5 kcal/mol), mouse Pgp favors closed TMDs and open NBDs, whereas Sav1866 favors the exact opposite configurations. These differences imply that mouse Pgp and Sav1866 employ rather different transport mechanisms, particularly in regard to the role of water.

Methods
Structure construction of outward-facing conformation of Pgp. Rigorous atomic modeling of three-dimensional (3D) protein structure requires correct primary amino acid sequence alignment and accurate 3D structural predictions for the gap regions in the alignment. In our case, an additional challenge included a template with fewer amino acid residues compared to the homology sequence (a Sav1866 dimer consists of 1156 residues whereas mouse Pgp contains 1282 residues). Therefore, Pgp has an additional ~10% of 3D structure information that must be gleaned from sources other than the alignment. An automatic homology modeling method (e.g., MODELLER) predicted unreasonable secondary structure for the gaps in the alignment. However, since the inward-facing conformation of mouse Pgp has been resolved, 3D structure corresponding to these gaps can be extended to the outward-facing conformation homology model prior to equilibration. In addition to combining both sequence and structural alignments, a rational homology modeling process should also carefully examine any effects of protein function manifested in differences between the template and the output structures. We used a rational and systematic approach of homology modeling to produce a plausible starting structure of the outward-facing conformation of mouse Pgp.
Figure 8 | Residue type comparison between mouse P-pg and Sav1866 at TMDs. Both proteins are drawn in cartoon: helices as tubes, beta-sheets as arrows, turn and coil as wires. The residues are colored by residue type: non-polar residues in white, polar-residues in green, basic residues in blue and acidic residues in red. There are only parallel and non-polar residues in the drug-binding pocket (A) of mouse Pgp whereas there are 9 pairs (18 total) charged residues in the same region of Sav1866 (B). The counterpart residues in the mouse P-pg are shown in text blocks: mouse P-pg half1 in red, half2 in blue, Sav1866 both halves in green. These residues are drawn in spheres from top view (C) for mouse P-pg and (D) for Sav1866.

a. Partial modeling based on sequence alignment on outward-facing Sav1866 crystal structure. Primary amino acid sequence alignments were generated using the EMBoss Needle pairwise alignment tool at the EMBL (https://www.ebi.ac.uk/Tools/psa/emboss_needle) using the PAM500 similarity matrix, a gap opening penalty of 50 and a gap extension penalty of 10 (Figure S7). To eliminate skewed alignments resulting from the Pgp linker region, a mouse Pgp monomer (1–1276) with linker omitted (residues 626–692) was aligned to two tandem copies of Sav1866 monomer with two C-terminal residues (577 and 578) removed from the first copy (i.e. 1–576 and 1–578). The resulting alignment revealed an extended Pgp N-terminus (1–47) that has no counterpart in Sav1866. These residues, including four C-terminal mouse Pgp residues (1273–1276) were trimmed, and the alignment was regenerated using the same parameters (Figure S7A). The final alignment revealed only four single and one double amino acid insertion for mouse Pgp and only one double insertion for Sav1866. Secondary structure obtained from both the Sav1866 crystal structure (PDB: 2ONJ) and mouse Pgp crystal structure (PDB: 4M1M) was overlaid above/below the respective amino acid sequence in the alignment (Figure S7A). The procedure revealed an impressive positional conservation of secondary structure between the bacterial- and mammalian- transporters, despite the very different protein conformations represented in the crystal structures. Exceptions in the form of secondary structure mismatches include mouse Pgp first transmembrane domain (TM1) and first extracellular loop (ECL1; residues 1–106), mouse Pgp ECL4 (residues 692 to 747), and Sav1866 TM1/ECL1 (residues 1–59). The final alignment (transporter core), using the same weighting parameters and omitting the secondary structure mismatches, resulted in a good overall amino acid sequence identity of 30%, a high degree of amino acid similarity of 63%, and unchanged positions of the insertions/deletions.

b. Model finalization using structural alignment on inward-facing Pgp crystal structure. Six gaps consisted of Pgp residues (Phe374, Pro398, Tyr1107, Pro1044, Ser1137 and Tyr1138) that were not represented in Sav1866, but all reside in coil loops that could easily accommodate the addition of each in their respective tertiary structure. The remaining two gaps were located in Pgp intracellular helix 1 (IH1) which was modeled to preserve the positioning of the conserved double aromatic motif (IH1: Trp158 and Phe159 and IH3: Trp799 and Phe800) present in the pseudo-symmetric counterpart IH3 whereas Asp801 and Asp802 was not modeled. The alignment was used as input to a PyMOL script that mutated the Sav1866 core (with TM1 and ECL1 removed) one residue at a time to Pgp side chains, taking advantage of optimal choice of side chain rotamers within PyMOL to minimize clashes. The homology structure has 0.78 Å root-mean-square deviation from the template structure of Sav1866 (Figure S7B). The missing residues and fragments were then truncated into the homology structure using fragments of the inward-facing conformation (PDB: 4M1M-A). Structure fragments of residue 30 to 107 (TM1), residue 681 to 747 (TM4/TM7) were added without disturbing the integrity of the connecting helices. In order to achieve maximum local structural alignment between the outward-facing homology model and the inward-facing crystal structure, loops corresponding to missing residues were replaced using the inward-facing crystal structure as the structural template. Specifically, fragment 368 to 385 in crystal structure (PDB: 4M1M) was aligned to the region with missing residue 374 and the same procedure was applied to the following: fragment 390 to 410 for missing residue 398, fragment 1009 to 1032 for missing residue 1017, fragment 793 to 808 for missing residues 801, 802, fragment 1034 to 1054 for missing residue 1044 and fragment 1129 to 1139 for missing residue 1137, 1138 (Figure S8). The rationale was to use the inward-facing crystal structures to model these gaps by transferring the corresponding secondary structure to the outward-facing homology model (Figure S9). In contrast, using automatic homology modeling program MODELLER generated incorrect structure folding in these regions (Figure S10).

c. Structure optimization and validation. The structure was then processed using Phenix to optimize protein geometry and Ramachandran favorability. The final protein geometry was evaluated using the MolProbity server, which reported 3.27% poor rotamers, 0.68% Ramachandran outliers, 95.4% Ramachandran favored, 0% Cα deviations (>0.25 Å), 0% bad backbone bonds and 0% bad backbone angles. In order to further examine the validity of the homology model, a morph calculation was performed for the transition between inward-facing (crystal structure) and outward-facing (homology model) conformations (Figure S11). The results revealed no incompatible helix and beta-sheet during the transitions. The positioning of TM5 is also validated by several previous disulfide crosslinking experiments on Pgp7–9 (Figure 1).

d. Modeling of MgATP binding. Mg<sup>2+</sup> coordinated ATP<sup>2−</sup> (MgATP<sup>2−</sup>) was chosen as the ligand for the NBDs of mouse Pgp. The homology template Sav1866 crystal structure has ATP in the ATP-binding sites but lacks Mg<sup>2+</sup> that is important for ATP hydrolysis. Therefore, MgACP as modeled in the crystal structure of the human mitochondrial solute transporter ABC10 in the inward-facing conformation (PDB code 4AYT)<sup>38</sup>, was used as template for the positioning of ATP in mouse Pgp because of 100% conservation of ATP binding residues between the two proteins. The β carbon in ACP was replaced with β oxygen to generate initial coordinates of MgATP<sup>2−</sup> (Figure 4).

All-atom molecular dynamics simulations. All MD simulations utilized CHARMM22 with the CMAP correction of all-atom protein force field<sup>40</sup> and CHARMM36 all-atom lipid force field<sup>41</sup>. The force field of ATP<sup>2−</sup> was implemented by CHARMM36 general force field<sup>42</sup>. Protein were placed in 120 × 120 × 120 Å POPC bilayer and dissolved in a water box of the padding distance maintains >12 Å from every direction in equilibrium. Free ions with the concentration of 0.15 M NaCl and 0.002 M of MgCl<sub>2</sub> were added to mimic physiological ionic condition and to neutralize the total system charge. All atomistic MD simulations were performed using NAMD2.9. The details of lipid-bilayer modeling and system control of 15 ns multi-step pre-equilibration and 200 ns production phase MD simulations are described in the Text S2. We will make the coordinate files produced in this study available upon request.

1. Linton, K. J. & Higgins, C. F. Structure and function of ABC transporters: the ATP switch provides flexible control. Pflugers Archiv: Eur J Physiol. 453, 555–567, doi:10.1007/s00424-006-0126-x (2007).
2. Raviv, Y., Pollard, H. B., Bruggemann, E. P., Pastan, I. & Gottesman, M. M. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J Biol Chem 265, 3975–3980 (1990).
3. Rogan, A. M., Hamilton, T. C., Young, R. C., Klecker, R. W., Jr. & Ozols, R. F. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224, 3 (1984).
4. Shen, D. W. et al. Human multidrug-resistant cell lines increased mdrl expression can precede gene amplification. *Science* **323**, 643 (1986).

5. Gottesman, M. M. & Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. *Annu Rev Biochem* **62**, 383–427 (1993).

6. Zomara, J. M., Pearce, H. L. & Beck, W. T. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. *Mol Pharmacol* **48**, 446–458 (1995).

7. Seelig, A. A general pattern for substrate recognition by P-glycoprotein. *Eur J Biochem* **251**, 252–261 (1998).

8. Schinkel, A. H., Wagenaar, E., Mol, C. A. & van Deemter, L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. *J Clin Invest* **97**, 2517–2524 (1996).

9. Ueda, K. et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. *J Bio Chem* **267**, 24248–24252 (1992).

10. Kuhnke, D. et al. MDRI-P-Glycoprotein (ABCBI) Mediates Transport of Alzheimer's amyloid-beta peptides—implications for the mechanisms of Abeta clearance at the blood-brain brain barrier. *Biochim Biophys Acta* **1760**, 347–353 (2007).

11. Shukla, S., Wu, C.-P. & Ambudkar, S. V. Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. *Expert Op Infect Drug Metab Toxicol* **4**, 205–223 (2008).

12. Aller, S. G. et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. *Science* **323**, 1718–1722, doi:10.1126/science.1168790 (2009).

13. Li, J., Jaimies, K. F. & Aller, S. G. Refined structures of mouse P-glycoprotein. *Protein Sci* **23**, 34–46, doi:10.1002/pro.2387 (2014).

14. Pascaud, C., Garrigos, M. & Orlowski, S. Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents. *J Biol Chem* **283**, 351–358 (1998).

15. Martin, C. et al. Communication between multiple drug binding sites on P-glycoprotein. *Mol Pharmacol* **58**, 624–632 (2000).

16. Smith, P. C. et al. ATP binding to the motor domain from an ABC transporter drives formation of a nucleotide sandwich dimer. *Mol Cell** **10**, 139–149 (2002).

17. Zaitzev, J. A. A structural analysis of asymmetry required for catalytic activity of an ABC-ATPase domain dimer. *EMBO J* **25**, 3432–3444 (2006).

18. Jardetzky, O. Simple allosteric model for membrane pumps. *Nature* **211**, 969–970 (1966).

19. Dawson, R. J. & Locher, K. P. Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP-PNP. *Nature* **489**, 287–291, doi:10.1038/nature11232 (2012).

20. Loo, T. W. & Clarke, D. M. Inhibition of oxidative cross-linking between N-terminal and central regions of the nucleotide-binding domains are linked closely together. *J Bio Chem* **285**, 24617–24624 (2010).

21. Van Helvoort, A. et al. PDR1, a human ABC transporter gene, is upregulated by hyperosmolar stress. *Annu Rev Biochem* **70**, 643 (1999).

22. Bocian, J. P., Zografos, G., Davis, L. & Aller, S. G. ATPase activity of many drugs. *J Bio Chem* **279**, 27482–27487 (1996).

23. Loo, T. W., Bartlett, M. C. & Clarke, D. M. ATPase activity of two bound nucleotides: implications for catalysis. *Biochemistry* **43**, 24617–24624, doi:10.1021/bi0179280 (2002).

24. Loo, T. W. & Clarke, D. M. Secondary and tertiary structure changes of reconstituted P-glycoprotein. A Fourier transform attenuated total reflection infrared spectroscopy analysis. *J Bio Chem* **271**, 24617–24624 (1996).

25. Loo, T. W. et al. Characterization of an asymmetric occluded state of P-glycoprotein with two bound nucleotides: implications for catalysis. *J Bio Chem* **285**, 7575–7586, doi:10.1074/jbc.M109047290 (2010).

26. Tomblin, G., Bartholomew, L., Gini, K., Tyndall, C. A. & Senior, A. E. Synergy between conserved ABC signature Ser residues in P-glycoprotein catalysis. *J Bio Chem* **279**, 5363–5373, doi:10.1074/jbc.M109164200 (2004).

27. O'Mara, M. L. & Mark, A. E. Structural characterization of two metastable ATP-bound states of P-glycoprotein. *PloS one* **9**, e91916, doi:10.1371/journal.pone.0091916 (2014).

28. Qu, Q., Russell, P. L. & Sharom, F. J. Stoichiometry and affinity of nucleotide binding to P-glycoprotein during the catalytic cycle. *Biochemistry* **42**, 1170–1177, doi:10.1021/bi205555 (2003).

29. Callaghan, R., Berridge, G., Ferry, D. R. & Higgins, C. F. The functional purification of P-glycoprotein is dependent on maintenance of a lipid-protein interface. *Biochim Biophys Acta* **1328**, 109–124 (1997).

30. van Helvoort, A. et al. MDRI P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. *Cell** **87**, 507–517 (1996).

31. Dali, A. & Overington, J. P. Function of rules for comparative protein modeling from a database of protein structure alignments. *Protein Sci* **3**, 1582–1596, doi:10.1002/pro.5560030923 (1994).

32. Shintre, C. A. et al. Structures of ABCB10, a human ATP-binding cassette transporter in apo- and nucleotide-bound states. *PNAS* **110**, 9710–9715, doi:10.1073/pnas.1217421110 (2013).

33. Kloda, J. B. et al. Update of the CHARMm all-atom additive force field for lipids: validation on six lipid types. *J Phys Chem B* **114**, 7830–7843, doi:10.1021/jp110759q (2010).

34. van Vlimmen, E., L. L. & Vugts, M. C. A. All-atom potential empirical force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. *J Comp Chem* **31**, 671–690, doi:10.1002/jcc.21367 (2010).

Acknowledgments

We acknowledge funding support from NIH grant DP2 OD008591 and XSEDE award TG-MCB140067.

Author contributions

L.P. and S.G.A. wrote the main manuscript text and L.P. prepared all figures. All authors reviewed the manuscript.

Additional information

Supplementary information accompanies this paper at http://www.nature.com/scientificreports/

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Pan, L. & Aller, S. G. Equilibrated Atomic Models of Outward-Facing P-glycoprotein and Effect of ATP Binding on Structural Dynamics. *Sci. Rep.* **5**, 7880; DOI:10.1038/srep07880 (2015).